Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes

References

• Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, International PCOS Network, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602–1618.
   PubMed Web of Science ®Google Scholar
• La Marca A, Broekmans FJ, Volpe A, et al. Anti-Mullerian hormone: what do we still need to know? Hum Reprod. 2009;24:2264–2275.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891–4899.
   PubMed Web of Science ®Google Scholar
• Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234:81–86.
   PubMed Web of Science ®Google Scholar
• Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:941–945.
   PubMed Web of Science ®Google Scholar
• Weenen C, Laven JS, Von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.
   PubMed Web of Science ®Google Scholar
• Casadei L, Madrigale A, Puca F, et al. The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol. 2013;29:545–550.
   PubMed Web of Science ®Google Scholar
• Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod. 2012;27:2494–2502.
   PubMed Web of Science ®Google Scholar
• de Kat AC, Verschuren WM, Eijkemans MJ, et al. Anti-Müllerian hormone trajectories are associated with cardiovascular disease in women: results from the doetinchem cohort study. Circulation. 2017;135:556–565.
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Margalioth EJ, Gal M, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod. 2005;20:1814–1819.
   PubMed Web of Science ®Google Scholar
• Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296:238–243.
   PubMed Web of Science ®Google Scholar
• Lin YH, Chiu WC, Wu CH, et al. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril. 2011;96:230–235.
   PubMed Web of Science ®Google Scholar
• Köninger A, Koch L, Edimiris P, et al. Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. Arch Gynecol Obstet. 2014;290:1023–1030.
   PubMed Web of Science ®Google Scholar
• Fraissinet A, Robin G, Pigny P, et al. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017;32:1716–1722.
   PubMed Web of Science ®Google Scholar
• Jacob SL, Field HP, Calder N, et al. Anti-Müllerian hormone reflects the severity of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;86:395–400.
   PubMed Web of Science ®Google Scholar
• Pastuszek E, Lukaszuk A, Kunicki M, et al. New AMH assay allows rapid point of care measurements of ovarian reserve. Gynecol Endocrinol. 2017;33:638–643.
   PubMed Web of Science ®Google Scholar
• Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. Fertil Steril. 2015;104:1016–1021.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rantala A, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab. 2012;97:1492–1500.
   PubMed Web of Science ®Google Scholar
• Piltonen T, Puurunen J, Hedberg P, et al. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Hum Reprod. 2012;27:3046–3056.
   PubMed Web of Science ®Google Scholar
• Puurunen J, Piltonen T, Jaakkola P, et al. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:1973–1978.
   PubMed Web of Science ®Google Scholar
• Cook CL, Siow Y, Brenner AG, et al. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141–146.
   PubMed Web of Science ®Google Scholar
• Mulders AG, Laven JS, Eijkemans MJ, et al. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004;19:2036–2042.
   PubMed Web of Science ®Google Scholar
• Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318–323.
   PubMed Web of Science ®Google Scholar
• Piltonen T, Morin-Papunen L, Koivunen R, et al. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1820–1826.
   PubMed Web of Science ®Google Scholar
• Sahmay S, Atakul N, Aydogan B, et al. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2013;92:1369–1374.
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Munkhzaya M, Iwasa T, et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J. 2017;64:531–541.
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013;98:3332–3340.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26:3123–3129.
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92:240–245.
   PubMed Web of Science ®Google Scholar
• Pierre A, Peigné M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod. 2013;28:762–769.
   PubMed Web of Science ®Google Scholar
• Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28:1077–1083.
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–5962.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Vanky E, Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod. 2009;24:1732–1738.
   PubMed Web of Science ®Google Scholar
• Cui Y, Shi Y, Cui L, et al. Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome. Fertil Steril. 2014;102:230–236.
   PubMed Web of Science ®Google Scholar
• Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016;33:15–28.
   PubMed Web of Science ®Google Scholar
• Cimino I, Casoni F, Liu X, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055.
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454–1460.
   PubMed Web of Science ®Google Scholar
• Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78:773–776.
   PubMed Web of Science ®Google Scholar
• Pinola P, Puukka K, Piltonen TT, et al. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertil Steril. 2017;107:788–795.
   PubMed Web of Science ®Google Scholar
• Lefebvre T, Dumont A, Pigny P, et al. Effect of obesity and its related metabolic factors on serum anti-Müllerian hormone concentrations in women with and without polycystic ovaries. Reprod Biomed Online. 2017;35:325–330.
   PubMed Web of Science ®Google Scholar
• de Kat AC, Broekmans FJ, Laven JS, et al. Anti-Müllerian hormone as a marker of ovarian reserve in relation to cardio-metabolic health: a narrative review. Maturitas. 2015;80:251–257.
   PubMed Web of Science ®Google Scholar
• Feldman RA, O'Neill K, Butts SF, et al. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome. Fertil Steril. 2017;107:276–281.
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.
   PubMed Web of Science ®Google Scholar